With a new built-for-purpose facility opening in the summer of 2022, Avid Bioservices’ expansion into viral vector manufacturing is poised to fill an observed unmet need in the space by prioritizing the specific needs of the unique process development and manufacturing of viral vectors — all while emphasizing quality and leveraging its legacy regulatory record.

Our management team expertise and commitment to a quality-first mindset, perfectly positions Avid to add value to clients in this growing space:

• With over 20 years of successful regulatory inspections, Avid can leverage this expertise and experience as we grow the viral vector space.
• A purpose-built viral vector manufacturing facility answers the need for quality, expertise, and safety in this unique market.
• The new world-class facility is designed with a flexible person-in-plant experience for clients.